Skip to main content

Pacific Biometrics Snags Two Clinical Biomarker Research Contracts

NEW YORK (GenomeWeb News) – Pacific Biometrics said today that it has been awarded two contracts worth a total of $1.6 million from an unnamed company to provide clinical services for use in rheumatoid arthritis drug development programs.
 
The Seattle-based firm said the contracts are part of a series of four contracts related to a global development program. PBI will offer testing for a panel of inflammatory, metabolic, cardiovascular, and musculoskeletal biomarkers to support its partner’s phase III clinical program.
 
PBI CEO Ron Helm said the agreements should “have a meaningful impact” on the company’s financials in 2009, 2010, and in 2011.
 
Helm also said that the drug in question “may have applicability to a broader range of inflammatory diseases” beyond rheumatoid arthritis.
 
Further financial terms of the agreements were not released.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.